Document Detail

Interaction of epoprostenol (PGI2) with vasoconstrictors on diameter of large coronary arteries of the dog.
MedLine Citation:
PMID:  6199604     Owner:  NLM     Status:  MEDLINE    
The platelet release products thromboxane A2 (TxA2) and serotonin (5-HT) might contribute to coronary vasoconstriction in humans. We have examined the effects of a TxA2-like analogue (U46619), 5-HT, and epoprostenol (PGI2) on the left anterior descending coronary artery of the dog. Changes in diameter were measured by sonomicrometry during perfusion of the vessel with blood from a support dog, at constant flow and distal resistance. Intra-arterial infusions of 5-HT (0.01-1 mumol/L) and U46619 (0.003-0.1 mumol/L) reduced external diameter of the artery (about 2.0 mm) by 0.12 mm and 0.16 mm, respectively. Intra-arterial PGI2 (0.01-0.1 mumol/L) increased the diameter of the artery (by 0.08 mm) and reduced blood pressure of the support dog (by 23 mm Hg), but did not significantly (p greater than 0.05) reduce the vasoconstrictor effects of either 5-HT (0.3 mumol/L) or U46619 (0.1 mumol/L) infused simultaneously. Indomethacin (5 mg/kg i.v.) doubled the direct dilator effect of PGI2, and increased the sensitivity of the artery to 5-HT (by 11.5-fold) and to U46619 (by 2.8-fold). After indomethacin infusion, intra-arterial PGI2 (0.1 mumol/L) reduced the constriction induced by continuous infusion of 5-HT or U46619. These data suggest that PGI2 may be of limited usefulness in preventing constriction of large coronary vessels because it causes hypotension. However, endogenous PGI2 produced by the coronary vessels or pericardium may modulate the influence of coronary vasoconstrictors, and these tissues are therefore potential targets for PGI2-releasing drugs.
G J Dusting; J A Angus
Related Documents :
7526254 - Vasculopathy of the anterior choroidal artery following intra-arterial chemotherapy--ca...
24933644 - Ex vivo bubble production from ovine large blood vessels: size on detachment and eviden...
6199604 - Interaction of epoprostenol (pgi2) with vasoconstrictors on diameter of large coronary ...
16159054 - Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by ...
9610834 - Endovascular grafting for abdominal aortic aneurysms: changing incidence and indication...
19190464 - Treatment of experimental aneurysms with an embolic-containing device and liquid emboli...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  6     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:    1984 Jan-Feb
Date Detail:
Created Date:  1984-03-29     Completed Date:  1984-03-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  20-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Coronary Vessels / drug effects*
Drug Interactions
Epoprostenol / pharmacology*
Indomethacin / pharmacology
Prostaglandin Endoperoxides, Synthetic / pharmacology
Serotonin / pharmacology
Vasoconstriction / drug effects
Vasoconstrictor Agents / pharmacology*
Vasomotor System / drug effects
Reg. No./Substance:
0/Prostaglandin Endoperoxides, Synthetic; 0/Vasoconstrictor Agents; 35121-78-9/Epoprostenol; 50-67-9/Serotonin; 53-86-1/Indomethacin; 76898-47-0/15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and...
Next Document:  Activation of the renin-angiotensin system by sodium nitroprusside in essential hypertension.